Tag: CAN

The acai (Euterpe oleracea) fruit is endemic to Central and South America, primarily in the Amazon jungle. Acai has grown in popularity as a...

Due to its potential to improve cognitive function, the chemical molecule dimethylaminoethanol (DMAE), commonly known as deanol, has attracted attention lately. The neurotransmitter acetylcholine,...

For decades, it was widely believed that brain development was largely complete by early adulthood. However, advancements in neuroscience have reshaped our understanding of the adult brain, revealing that it continues to grow, adapt, and form new neural connections throughout life. The phenomenon of brain development in adults is a testament to the brain’s plasticity, enabling cognitive growth, skill acquisition, and resilience against neurodegeneration. Understanding adulthood brain development is crucial for maintaining cognitive function, mental health, and overall well-being.

Memory loss, particularly from dementia and Alzheimer's disease, is a growing concern worldwide. It affects millions of individuals and their families, posing significant challenges to healthcare systems. Historically, treatment options have been limited. They often focus on managing symptoms rather than addressing the underlying disease processes. However, the landscape of memory loss treatment is changing. Recent breakthroughs in medication are offering new hope for patients and their families. One such breakthrough is donanemab, a new medication that targets the amyloid-beta plaques associated with Alzheimer's disease. Its potential effectiveness in slowing cognitive decline has sparked significant interest in the medical community. This article will delve into the details of these new medications, their mechanisms of action, and their potential impact on patients' lives. We'll compare donanemab with donepezil, a commonly prescribed Alzheimer's medication, and discuss the implications of the FDA's accelerated approval of new Alzheimer's drugs.